Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy

Tanaka, Masao; Kitajima, Yoshihiko; Sato, Seiji; Miyazaki, Kohji

doi:10.1002/bjs.4014

Cited by 22 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no significant differences between two groups (P =0.95) appear to have a favorable outcome. We here showed expression of MUC5AC and MUC2 demonstrated in 60 (33.9%) and 60 (33.9%) of the 177 gastric cancers, which is compatible with previous studies (Lee et al 2001;Lee et al 2003;Tanaka et al 2003;Pinto-de-Sousa et al 2002). Villin is a useful intestinal phenotypic marker detected in the brush border on luminal surfaces and is associated with Cdx2 expression (Tatematsu et al 2003;Werling et al 2003).…”

Section: Discussionsupporting

confidence: 77%

Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis

Mizoshita

Tsukamoto

Nakanishi

et al. 2003

Journal of Cancer Research and Clinical Oncology

114

147

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis

Mizoshita

Tsukamoto

Nakanishi

et al. 2003

Journal of Cancer Research and Clinical Oncology

114

147

View full text Add to dashboard Cite

show abstract

“…While we noted its highest expression in the well and moderately differentiated tubular carcinoma which supported the view on its contribution to tubular structure formation [19] . Although some studies showed that MUC1 expression in gastric cancers was negatively correlated with the expression of E-cadherin [20] , we found the positive relationships between them, what's more, the correlation of MUC1, MUC2 and Ecadherin were first studied by us. Both MUC1 and MUC2 might contribute to the progress of gastric cancer, and they might restrain the role of E-cadherin.…”

Section: Discussionmentioning

confidence: 56%

Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance

Zhang

Zhang²,

Zhao³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM:To investigate the expression of three types of mucin (MUC1, MUC2, MUC5AC) and E-cadherin in human gastric carcinomas and their clinical significance. METHODS:Ninety-four gastric cancer specimens were classified according to WHO criteria and detected by immunohistochemical assay of expression of mucins and E-cadherin. RESULTS:The positive expression rates of MUC1, MUC2, MUC5AC and E-cadherin were 82% (77/94), 84% (79/94), 40% (38/94) and 56% (53/94) respectively. MUC1 expression was significantly correlated with the types of cancer (the positive rates of MUC1 in well and moderately differentiated tubular adenocarcinoma, poorly differentiated adenocarcinoma, signet-ring cell carcinoma and mucinous carcinoma were 91%, 87%, 71%, 71%, respectively, P<0.05), age of patients (the positive rates of it among the people who are younger than 40 years, between 40-60 years and over 60 year were 74%, 81%, 89%, P<0.05), lymph nodes involvement (the positive rates in the non-interfered group and the interfered group were 78%, 85%, P<0.05) and tumor size (the positive rates in the tumors with the size less than 3 cm, 3-6 cm and larger than 6 cm were 69%, 92%, 69%, P<0.05); MUC2 expression was significantly associated with types of cancers and had the strongest expression in mucinous carcinomas (the positive rates of MUC2 in well and moderately differentiated tubular adenocarcinoma, poorly differentiated adenocarcinoma, signet-ring cell carcinoma and mucinous carcinoma were 94%, 70%, 81%, 100%, P<0.05), but it had no obvious relation to age, gender, tumor location, lymph nodes involvement, depth of invasion and metastasis to extra-gastric organs (P>0.05); MUC5AC expression was not related to any of the characteristics investigated except that it had relation to gender, whereas MUC5AC showed the tendency to higher expression in less invasive lesions and lower expression in advanced stage cancers (P>0.05); No significant difference was found for E-cadherin expression. There were strong positive relationships between the expression of MUC1 and E-cadherin, MUC2 and E-cadherin, MUC1 and MUC2 (R = 0.33, R = 0.22, R = 0.32, respectively, P<0.05). According to the COX proportional hazards model, older patients, involvement of lymph nodes, different types of gastric cancer and MUC2 expression were significantly associated with poorer outcome of gastric carcinoma patients (β = 0.08, β = 3.94, β = 1.33, β = 0.75, respectively, P<0.05).CONCLUSION: MUC1 and MUC2 are good markers of different types of gastric cancer. MUC2 is especially a good marker of mucinous carcinoma. MUC1, MUC2 may interfere with the function of E-cadherin in gastric carcinomas, and have synergic effect on progression of gastric cancers.Zhang HK, Zhang QM, Zhao TH, Li YY, Yi YF. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance.

show abstract

“…This impaired adhesion status is clearly correlated with a haematogenous spread of the primary tumor cells, is an independent predictive marker for lymph node or distant metastasis, and for disease recurrence of many kinds of cancers including breast, colorectal, gastric, colorectal, esophageal, prostate, etc. (Aoki et al 2003;Asgeirsson et al 2000;Bankfalvi et al 2002;Chow et al 2001;Ikeguchi et al 2000;Loric et al 2001;Rhodes et al 2003;Tanaka et al 2003). It is also a significantly poor prognostic factor for survival (Shnayder et al 2001;Sugio et al 2002).…”

Section: E-cadherin and Beta-cateninsmentioning

confidence: 91%

Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

Qin

Tang

2004

J Cancer Res Clin Oncol

173

148

View full text Add to dashboard Cite

Molecular markers (biomarkers) for hepatocellular carcinoma (HCC) metastasis and recurrence could provide additional information to that gained from traditional histopathological features. A large number of biomarkers have been shown to have potential predictive significance. One important aspect of this is to detect the transcripts of tumor-associated antigens (such as AFP, MAGEs, and CK19), which are proposed as predictive markers of HCC cells disseminated into the circulation and for metastatic recurrence. Another important aspect is to analyze the molecular markers for cellular malignancy phenotype, including DNA ploidy, cellular proliferation index, cell cycle regulators, oncogenes, and tumor suppressors (especially p53 gene), as well as telomerase activity. Molecular factors involved in the process of HCC invasion and metastasis, including adhesion molecules (E-cadherin, catenins, ICAM-1, laminin-5, CD44 variants, osteopontin), proteinases responsible for the degradation of extracellular matrix (MMPs, uPA system), as well as angiogenesis regulators (such as VEGF, intratumor MVD), have also been shown to be potential predictors for HCC metastatic recurrence and clinical outcomes. One important new trend is to widely delineate biomarkers with genomic and proteomic expression with reference to predicting metastatic recurrence, molecular diagnosis, and classification, which has been drawing more attention recently. Body fluid (particularly blood and urine) testing for biomarkers is easily accessible and more useful in clinical patients. The prognostic significance of circulating DNA in plasma or serum and its genetic alterations is another important direction. More attention should be paid to these areas in the future. As understanding of tumor biology deepens, more and more new biomarkers with high sensitivity and specificity for HCC metastatic recurrence could be found and routinely used in clinical assays. However, the combination of the pathological features and some of the biomarkers mentioned above seems to be more practical up to now.

show abstract

Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy

Cited by 22 publications

References 25 publications

Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis

Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis

Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance

Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

Contact Info

Product

Resources

About